|
| 37978284 | The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. | Nat Med | 2024 |
| 37944912 | Pediatric low-grade glioma: State-of-the-art and ongoing challenges. | Neuro Oncol | 2024 |
| 37978284 | The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. | Nat Med | 2024 |
| 37875569 | Author Correction: Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology. | Nat Med | 2024 |
| 37944912 | Pediatric low-grade glioma: State-of-the-art and ongoing challenges. | Neuro Oncol | 2024 |
| 37875569 | Author Correction: Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology. | Nat Med | 2024 |
| 35977048 | BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma. | Neuro Oncol | 2023 |
| 36181342 | ERBB and P-glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P-glycoprotein. | Mol Oncol | 2023 |
| 35882450 | The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models. | Neuro Oncol | 2023 |
| 36255618 | Evaluation of Antitumor and On-Target Activity of HDAC Inhibitors with the Zebrafish Embryo Xenograft Model. | Methods Mol Biol | 2023 |
| 35977048 | BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma. | Neuro Oncol | 2023 |
| 37738646 | Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation. | Neuro Oncol | 2023 |
| 37733309 | Dabrafenib plus Trametinib in Pediatric Glioma with <i>BRAF</i> V600 Mutations. | N Engl J Med | 2023 |
| 37643378 | Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory <i>BRAF</i> V600-Mutant Pediatric High-Grade Glioma. | J Clin Oncol | 2023 |
| 37783879 | Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells. | J Neurooncol | 2023 |
| 37776353 | Genetical and epigenetical profiling identifies two subgroups of pineal parenchymal tumors of intermediate differentiation (PPTID) with distinct molecular, histological and clinical characteristics. | Acta Neuropathol | 2023 |
| 36959034 | Corrigendum to 'Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry' [Eur J Cancer 180 (2023) 71-84]. | Eur J Cancer | 2023 |
| 36639156 | Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation. | J Immunother Cancer | 2023 |
| 37075810 | LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients. | Neuro Oncol | 2023 |
| 37260252 | Neurosurgical morbidity in pediatric supratentorial midline low-grade glioma: Results from the German LGG studies. | Int J Cancer | 2023 |
| 36871657 | Cerebellar Mutism Syndrome After Posterior Fossa Tumor Surgery in Children-A Retrospective Single-Center Study. | World Neurosurg | 2023 |
| 37441736 | Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies. | Clin Pharmacol Ther | 2023 |
| 37379234 | Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. | Neuro Oncol | 2023 |
| 37308967 | Beyond germline genetic testing - heterozygous pathogenic variants in PMS2 in two children with Osteosarcoma and Ependymoma. | Hered Cancer Clin Pract | 2023 |
| 37183219 | Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells. | J Neurooncol | 2023 |
| 36933012 | Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions. | Acta Neuropathol | 2023 |
| 36542877 | Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry. | Eur J Cancer | 2023 |
| 36928815 | Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology. | Nat Med | 2023 |
| 37364231 | Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM. | JCO Precis Oncol | 2023 |
| 36459208 | Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts. | Acta Neuropathol | 2023 |
| 37500667 | MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas. | Nat Commun | 2023 |
| 37541273 | Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. | Lancet Oncol | 2023 |
| 37783879 | Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells. | J Neurooncol | 2023 |
| 37738646 | Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation. | Neuro Oncol | 2023 |
| 37776353 | Genetical and epigenetical profiling identifies two subgroups of pineal parenchymal tumors of intermediate differentiation (PPTID) with distinct molecular, histological and clinical characteristics. | Acta Neuropathol | 2023 |
| 37733309 | Dabrafenib plus Trametinib in Pediatric Glioma with <i>BRAF</i> V600 Mutations. | N Engl J Med | 2023 |
| 37541273 | Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. | Lancet Oncol | 2023 |
| 37500667 | MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas. | Nat Commun | 2023 |
| 37643378 | Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory <i>BRAF</i> V600-Mutant Pediatric High-Grade Glioma. | J Clin Oncol | 2023 |
| 36959034 | Corrigendum to 'Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry' [Eur J Cancer 180 (2023) 71-84]. | Eur J Cancer | 2023 |
| 37183219 | Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells. | J Neurooncol | 2023 |
| 37379234 | Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. | Neuro Oncol | 2023 |
| 37441736 | Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies. | Clin Pharmacol Ther | 2023 |
| 37308967 | Beyond germline genetic testing - heterozygous pathogenic variants in PMS2 in two children with Osteosarcoma and Ependymoma. | Hered Cancer Clin Pract | 2023 |
| 37075810 | LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients. | Neuro Oncol | 2023 |
| 37364231 | Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM. | JCO Precis Oncol | 2023 |
| 37260252 | Neurosurgical morbidity in pediatric supratentorial midline low-grade glioma: Results from the German LGG studies. | Int J Cancer | 2023 |
| 36542877 | Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry. | Eur J Cancer | 2023 |
| 36871657 | Cerebellar Mutism Syndrome After Posterior Fossa Tumor Surgery in Children-A Retrospective Single-Center Study. | World Neurosurg | 2023 |
| 36639156 | Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation. | J Immunother Cancer | 2023 |